NCT04916860|Unknown
Loading search results
Sponsor study identifier
interventional
100
1 country
1
Study Start
January 27, 2021
Actual (reported)Primary Completion
January 31, 2023
Actual (reported)Study Completion
March 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of relapsed and refractory CD7+ T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 27, 2021
Actual (reported)June 1, 2021
Actual (reported)June 8, 2021
Actual (reported)January 31, 2023
Actual (reported)March 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Safety: Incidence and severity of adverse events
To evaluate the possible adverse events occurred within first one month after CD7 CAR-T infusion, including the incidence and severity of symptoms such as cytokine release syndrome and neurotoxicity
First 1 month post CAR-T cells infusion
Remission Rate
To obsere the efficacy of CAR-T cells after infusion, complete remission (CR), complete remission with incomplete recovery of blood cells (CRi), minimal tumor residual positive(MRD+) or negative (MRD-) CR/CRi, disease recurrence or progression (PD) will be used for evaluation.
3 months post CAR-T cells infusion
duration of response (DOR)
24 months post CAR-T cells infusion
CAR-T proliferation
3 months post CAR-T cells infusion
progression-free survival (PFS)
24 months post CAR-T cells infusion
Cytokine release
First 1 month post CAR-T cells infusion
CAR-T proliferation
3 months post CAR-T cells infusion
Patients will be treated with CD7 CAR-T cells
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Hebei yanda Ludaopei Hospital
Beijingcun, Hebei, China
Cao XY, Zhang JP, Wei ZJ, Lu Y, Zhao YL, Xiong M, Zhou JR, Wang Y, Yang JF, Zhang X, Li J, Lu P. Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma. Transplant Cell Ther. 2026 Aug;32(8):956.e1-956.e13. doi: 10.1016/j.jtct.2026.05.045. Epub 2026 Jun 1.
First Submitted
June 1, 2021
First Posted
June 8, 2021
Study Start
January 27, 2021
Actual (reported)Primary Completion
January 31, 2023
Actual (reported)Contact the study team to confirm eligibility.
Study Completion
March 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 31, 2023
Record last verified: 2023-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: